Our ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the ADP-A2M4 (MAGE-A4) family of cancer testis antigens expressed in a number of solid tumor cell types. The ADP-A2M4 (MAGE-A4) antigen is among the most commonly expressed cancer testis antigens. The clinical study for our ADP-A2M4 (MAGE-A4) SPEAR T-cell is a phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity in certain patients with urothelial (bladder) cancers, melanoma, head and neck cancer, ovarian cancer, NSCLC, esophageal cancer, gastric cancers, synovial sarcoma, and MRCLS1.